9-Hydroxyellipticin free base
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407424

CAS#: 51131-85-2 (free base)

Description: 9-hydroxyellipticine, also known as IGIG 929 and LS133324, is a potent cytotoxic and antitumor agent. Structurally, 9-hydroxyellipticine is a 9-hydroxy derivative of ellipticine. The hydroxy group in 9-hydroxyellipticines increases the apparent affinity for DNA, stabilisation of toposiomerase II-DNA cleavable complex, oxidation to reactive quinone-imine intermediates, phosphorylation of p53 suppressor proteins and cytotoxicity relative to the parent ellipticines.


Price and Availability

Size Price Shipping out time Quantity
100mg USD 1050 2 Weeks
200mg USD 1850 2 Weeks
500mg USD 2850 2 Weeks
1g USD 3450 2 Weeks
2g USD 5250 2 Weeks
5g USD 8650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-23. Prices are subject to change without notice.

9-Hydroxyellipticin free base, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 407424
Name: 9-Hydroxyellipticin free base
CAS#: 51131-85-2 (free base)
Chemical Formula: C17H14N2O
Exact Mass: 262.1106
Molecular Weight: 262.312
Elemental Analysis: C, 77.84; H, 5.38; N, 10.68; O, 6.10


Related CAS #: 51131-85-2 (free base)   52238-35-4 (HCl)   58447-24-8 (methiodide).  

Synonym: 9-hydroxyellipticine; Hydroxyellipticine; 9-Hydroxyellipticin; NSC 210717; IGIG 929; IGIG929; IGIG-929; LS133324; LS-133324; LS 133324

IUPAC/Chemical Name: 5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol

InChi Key: QZTWUDDGLIDXSE-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H14N2O/c1-9-14-8-18-6-5-12(14)10(2)17-16(9)13-7-11(20)3-4-15(13)19-17/h3-8,19-20H,1-2H3

SMILES Code: OC1=CC2=C(NC3=C2C(C)=C(C=NC=C4)C4=C3C)C=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Harding MM, Grummitt AR. 9-hydroxyellipticine and derivatives as chemotherapy agents. Mini Rev Med Chem. 2003 Mar;3(2):67-76. Review. PubMed PMID: 12570841.

2: Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Matsumoto T. Cardioprotective effects of 9-hydroxyellipticine on ischemia and reperfusion in isolated rat heart. Jpn J Pharmacol. 2002 May;89(1):21-8. PubMed PMID: 12083739.

3: Sugikawa E, Tsunoda S, Nakanishi N, Ohashi M. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein. Anticancer Res. 2001 Jul-Aug;21(4A):2671-5. PubMed PMID: 11724337.

4: Mizumoto K, Sato N, Kusumoto M, Niiyama H, Maehara N, Nishio S, Li Z, Ogawa T, Tanaka M. Diverse effects of 9-hydroxyellipticine on the chemosensitivity of human pancreatic cancer cells harboring p53 mutations. Cancer Lett. 2000 Feb 28;149(1-2):85-94. PubMed PMID: 10737712.

5: Sugikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N, Ohashi M. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res. 1999 Jul-Aug;19(4B):3099-108. PubMed PMID: 10652599.

6: Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J, Jacquemin-Sablon H, Jacquemin-Sablon A. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors. Cancer Res. 1999 Oct 1;59(19):4927-36. PubMed PMID: 10519406.

7: Sato N, Mizumoto K, Kusumoto M, Niiyama H, Maehara N, Ogawa T, Tanaka M. 9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells. FEBS Lett. 1998 Dec 18;441(2):318-21. PubMed PMID: 9883907.

8: Ismail MA, Sanders KJ, Fennell GC, Latham HC, Wormell P, Rodger A. Spectroscopic studies of 9-hydroxyellipticine binding to DNA. Biopolymers. 1998 Sep;46(3):127-43. PubMed PMID: 9741963.

9: Elcock AH, Rodger A, Richards WG. Theoretical studies of the intercalation of 9-hydroxyellipticine in DNA. Biopolymers. 1996 Sep;39(3):309-26. PubMed PMID: 8756512.

10: Ohashi M, Sugikawa E, Nakanishi N. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res. 1995 Sep;86(9):819-27. PubMed PMID: 7591958.